The pharmaceutical sector’s transformation has bought many opportunities for market disrupters. In this context, Alvogen has successfully established itself as a multibillion-dollar company

The US generic pharmaceuticals market is transforming thanks to the consolidation of smaller industry players, which has resulted in price erosion

Courage and persistence are critical to good leadership, explains the Alvogen chairman and CEO

The founder and CEO of Alvogen shows us the napkin on which he first pitched his vision for the generic pharmaceuticals business

Robert Wessman explains that with just three US companies controlling half the world’s pharmaceutical sales, 100+ generics companies are unsustainable